CRNX Stock Risk & Deep Value Analysis
Crinetics Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About CRNX Stock
We analyzed Crinetics Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CRNX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
CRNX Risk Analysis & Red Flags
What Could Go Wrong
Despite promising early signs, the commercialization of paltusotine could fail to achieve anticipated market penetration due to unforeseen prescriber hesitancy or patient adherence issues. This would significantly impact revenue forecasts and delay the path to profitability, potentially requiring further dilutive funding.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Low
Red Flags
- ⚠
Resignation of Chief Development & Operating Officer, potentially creating a leadership vacuum.
- ⚠
Ongoing insider sales (albeit largely tax-related under 10b5-1 plans) could signal a lack of aggressive bullishness from management.
- ⚠
Analyst price target reduction (Citizens $105 -> $96) suggests some recalibration of expectations.
Upcoming Risk Events
- 📅
Departure of Chief Development & Operating Officer Jeff Knight (effective ~April 10, 2026)
- 📅
Slower-than-expected commercial adoption of paltusotine
- 📅
Negative results or delays in clinical trials for pipeline candidates
- 📅
Increased competitive pressure from new or existing therapies (no data specified, but general risk)
When to Reconsider
- 🚪
Paltusotine quarterly revenue growth significantly decelerates or misses analyst consensus for two consecutive quarters.
- 🚪
Cash burn accelerates significantly without commensurate revenue growth or positive pipeline news.
- 🚪
Critical pipeline assets fail in late-stage clinical trials or face unexpected regulatory hurdles.
Unlock CRNX Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Crinetics Pharmaceuticals Inc (CRNX) Do?
Market Cap
$3.19B
Sector
Healthcare
Industry
Biotechnology
Employees
437
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Visit Crinetics Pharmaceuticals Inc WebsiteInvestment Thesis
Crinetics Pharmaceuticals is a high-growth biotech with a de-risked lead asset (paltusotine) poised to disrupt the acromegaly market with its oral formulation, validated by strong initial commercialization. Supported by a robust balance sheet and a promising pipeline, the company is strategically positioned for significant market leadership and potential 10x growth as sales ramp up and pipeline assets advance.
Is CRNX Stock Undervalued?
Unlock the full AI analysis for CRNX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CRNX Price Targets & Strategy
12-Month Target
$96.00
Bull Case
$120.00
Bear Case
$45.00
Valuation Basis
Based on Citizens' $96 price target, implying a significant re-rating towards 2.6x current market cap, driven by paltusotine's commercial ramp and pipeline potential.
Entry Strategy
Dollar-cost average between $35-$40, targeting recent support levels. Consider scaling in on any market-wide or sector-specific dips.
Exit Strategy
Take partial profits at $90-$100 (analyst target zone) and hold a core position for potential 10x long-term growth. Consider stop-loss below $30.
Portfolio Allocation
7-10% for aggressive risk tolerance; 3-5% for moderate risk tolerance, reflecting high growth potential balanced with commercialization risks.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is CRNX Financially Healthy?
Valuation
P/E Ratio
-6.82
Price/Book
2.72
Profitability
Return on Equity
-36.94%
EPS
$-4.12
Balance Sheet
Current Ratio
12.32
Quick Ratio
12.09
Debt/Equity
0.05
Cash Flow
EBITDA
-$419.62M
Other
Beta (Volatility)
0.23
Does CRNX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The oral delivery mechanism for acromegaly offers a significant and durable advantage, supported by intellectual property. This moat should persist as long as paltusotine maintains its differentiated profile and effective patent protection, making it challenging for competitors to replicate quickly.
Moat Erosion Risks
- •Development of next-generation or superior oral therapies by competitors
- •Patent challenges or expiry, leading to generic competition
- •Lack of success in expanding paltusotine's indications or developing other pipeline assets
CRNX Competitive Moat Analysis
Sign up to see competitive advantages
CRNX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - No specific data available, but typically positive among investors tracking early-stage biotech commercialization.
Institutional Sentiment
Positive - Citizens maintained 'Market Outperform' despite a minor price target adjustment, indicating continued conviction.
Insider Activity (Form 4)
CEO Richard Scott Struthers sold 21,981 shares ($821,513) for RSU tax withholding on 2026-03-16. CSO Stephen F. Betz sold 10,612 shares ($396,610) for RSU tax withholding on 2026-03-16. Director Dana Pizzuti sold 5,000 shares ($202,234) on 2026-03-02, 5,000 shares ($247,485.50) on 2026-02-02, and 5,000 shares ($232,590.50) on 2026-01-02, all under 10b5-1 plans. Director Vivaldi Coelho Rogerio also sold shares ($180k total) under a 10b5-1 plan adopted 2025-12-11. No insider buys reported.
Options Flow
Normal options activity - No specific data indicating unusual institutional options positioning.
Earnings Intelligence
Next Earnings
Estimated late April / early May 2026 (for Q1 2026 results)
Surprise Probability
Medium - The company beat Q4 2025 estimates, suggesting potential for continued positive surprises if commercial ramp-up is strong.
Historical Earnings Pattern
Limited historical data; the stock reacted positively to the Q4 2025 revenue beat, indicating investor focus on commercial execution.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A - No specific competitive data provided in research.
Market Share Trend
Potentially gaining - Paltusotine is a new oral therapy entering the acromegaly market, likely taking share from existing injectable treatments due to convenience.
Valuation vs Peers
N/A - No specific valuation metrics or peer comparisons provided in research. Generally, early-stage biotechs with recently launched products may trade at high price-to-sales multiples based on future peak sales potential.
Competitive Advantages
- •First-in-class oral somatostatin receptor ligand for acromegaly (paltusotine) offering patient convenience
- •Robust cash position (> $1.38B) providing long runway for commercialization and R&D
- •Experienced leadership team with a track record in endocrine drug development
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive CRNX Stock Higher?
Near-Term (0-6 months)
- •Continued robust commercial ramp-up of paltusotine sales throughout 2026
- •Q1 2026 Earnings Report (estimated late April / early May 2026)
- •Positive updates from ongoing clinical trials for pipeline assets (e.g., small molecule therapies)
Medium-Term (6-18 months)
- •Expansion of paltusotine market share in acromegaly, potentially gaining significant ground from injectables
- •Advancement of lead pipeline candidates into later-stage clinical trials
- •Potential for new indications or geographic market expansion for paltusotine
Long-Term (18+ months)
- •Establishment as a market leader in rare endocrine diseases with a diversified oral pipeline
- •Potential for strategic partnerships or licensing agreements for pipeline assets
- •Significant revenue inflection point as paltusotine reaches peak sales
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CRNX?
- ✓
Sustained acceleration in paltusotine quarterly sales above analyst expectations
- ✓
Positive clinical data readouts for CRN04777 (for congenital adrenal hyperplasia) or other key pipeline assets
- ✓
Maintenance of strong cash position and prudent capital allocation
Bull Case Analysis
See what could go right with Premium
Competing with CRNX
See how Crinetics Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Crinetics Pharmaceuticals Inc CRNX | $3.2B | 8.9 | -6.8 | $1.4M | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Crinetics Pharmaceuticals Inc (CRNX)?
As of April 4, 2026, Crinetics Pharmaceuticals Inc has a DVR Score of 8.9 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Crinetics Pharmaceuticals Inc?
Crinetics Pharmaceuticals Inc's market capitalization is approximately $3.2B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Crinetics Pharmaceuticals Inc use?
CRNX is the ticker symbol for Crinetics Pharmaceuticals Inc. The company trades on the NMS.
What is the risk level for CRNX stock?
Our analysis rates Crinetics Pharmaceuticals Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of CRNX?
Crinetics Pharmaceuticals Inc currently has a price-to-earnings (P/E) ratio of -6.8. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Crinetics Pharmaceuticals Inc's revenue growing?
Crinetics Pharmaceuticals Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is CRNX stock profitable?
Crinetics Pharmaceuticals Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the CRNX DVR analysis updated?
Our AI-powered analysis of Crinetics Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 4, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CRNX (Crinetics Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.